计算溶液所需的质量、体积或浓度。
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 2 篇同行评审文献引用。
Belnacasan (VX-765) 是 VRT-043198 的口服生物活性前体,VRT-043198 是有效选择性的 IL 转换酶 (ICE)/caspase-1 抑制剂,对 caspase-1 的 Ki 值为 0.8 nM,对 caspase-4 的 Ki 值小于 0.6 nM。Belnacasan (VX-765) 作用于外周血单核细胞,可抑制 LPS 诱导的 IL-1β 和 IL-18 释放,IC50 约为 0.7 μM。
产品介绍:
Belnacasan (VX-765)是一种有效的选择性caspase-1抑制剂,无细胞试验中Ki为0.8 nM。
Information
Belnacasan (VX-765) is a potent and selective inhibitor ofcaspase-1withKiof 0.8 nM in a cell-free assay. Phase 2.
In vitro
VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1β release from both PBMCs and whole blood with IC50 of 0.67 μM and 1.9 μM, respectively.
In vivo
In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1β production by about 60%, and results in a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes. In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1β increase in forebrain astrocytes without significant effect on afterdischarge duration. In the mouse model of acute seizures, VX-765 (50 mg/kg-200 mg/kg) produces the anticonvulsant effect by delaying the time to onset of the first seizure and decreasing the number of seizures as well as their total duration by average 50% and 64%. In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1β biosynthesis.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥97%
| ALogP | 2.3 |
|---|